liothyronine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1585	6893-02-3

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: liothyronine liothyronine sodium triiodothyronine liothyronin

A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. Molecular weight: 650.98 Formula: C15H12I3NO4 CLOGP: 2.63 LIPINSKI: 1 HAC: 5 HDO: 3 TPSA: 92.78 ALOGS: -4.52 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mcg	O
60	mcg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ

Approvals:

Date	Agency	Company	Orphan
May 8, 1956	FDA	KING PHARMS R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthyroidism	98.45	33.34	18	219	2079	2355769
Hypothyroidism	73.52	33.34	16	221	4441	2353407
Palpitations	66.02	33.34	19	218	16437	2341411
Drug ineffective	64.98	33.34	30	207	101594	2256254
Feeling abnormal	59.28	33.34	19	218	23562	2334286
Completed suicide	53.02	33.34	17	220	21017	2336831
Product substitution issue	50.06	33.34	12	225	5057	2352791
Alopecia	48.20	33.34	16	221	21985	2335863
Fatigue	44.56	33.34	22	215	84851	2272997
Malaise	43.40	33.34	19	218	55566	2302282
Product quality issue	41.03	33.34	12	225	10817	2347031
Thyroid function test abnormal	40.18	33.34	7	230	600	2357248
Weight increased	40.08	33.34	14	223	22323	2335525
Rhinovirus infection	37.51	33.34	6	231	305	2357543
Urticaria	35.20	33.34	13	224	24248	2333600
Acute respiratory distress syndrome	33.52	33.34	8	229	3284	2354564

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event

Pharmacologic Action:

Source	Code	Description
ATC	H03AA02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones
ATC	H03AA03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY THYROID PREPARATIONS Thyroid hormones
FDA EPC	N0000175946	l-Triiodothyronine
FDA CS	M0021977	Triiodothyronine

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Goiter	indication	3716002	DOID:12176
Myxedema coma	indication	21263006
Hypothyroidism	indication	40930008	DOID:1459
Myxedema	indication	43153006	DOID:11634
Congenital hypothyroidism	indication	190268003	DOID:0050328
Simple goiter	indication	267369002
Malignant tumor of thyroid gland	indication	363478007	DOID:1781
T3 Suppression for Thyroid Function Test	indication
Mild Hypothyroidism	indication
Diagnostic Test for Thyroid Dysfunction	indication
Myocardial infarction	contraindication	22298006	DOID:5844
Thyrotoxic crisis	contraindication	29028009	DOID:12837
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Osteoporosis	contraindication	64859006	DOID:11476
Diabetes mellitus	contraindication	73211009	DOID:9351
Hypopituitarism	contraindication	74728003	DOID:9406
Angina pectoris	contraindication	194828000
Osteopenia	contraindication	312894000
Primary adrenocortical insufficiency	contraindication	373662000
Disorder of coronary artery	contraindication	414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.08	acidic
pKa2	8.12	acidic
pKa3	8.77	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Thyroid hormone receptor alpha	Nuclear hormone receptor	P10827	THA_HUMAN	AGONIST	Kd	10.24		CHEMBL	CHEMBL
Thyroid hormone receptor beta	Nuclear hormone receptor	P10828	THB_HUMAN	AGONIST	Ki	10.10		CHEMBL	CHEMBL
THAP domain-containing protein 1	Unclassified	Q9NVV9	THAP1_HUMAN		EC50	9		WOMBAT-PK
Proliferating cell nuclear antigen	Unclassified	P12004	PCNA_HUMAN		IC50	5.44		CHEMBL
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRA1_HUMAN GBRA2_HUMAN GBRA3_HUMAN GBRA4_HUMAN GBRA5_HUMAN GBRA6_HUMAN GBRB1_HUMAN GBRB2_HUMAN GBRB3_HUMAN GBRD_HUMAN GBRE_HUMAN GBRG1_HUMAN GBRG2_HUMAN GBRG3_HUMAN GBRP_HUMAN GBRT_HUMAN		IC50	4.64		CHEMBL
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	6.62		DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		EC50	6.30		WOMBAT-PK
GABA-A receptor; anion channel	Ion channel		GBRA1_RAT GBRA2_RAT GBRA3_RAT GBRA4_RAT GBRA5_RAT GBRA6_RAT GBRB1_RAT GBRB2_RAT GBRB3_RAT GBRD_RAT GBRE_RAT GBRG1_RAT GBRG2_RAT GBRG3_RAT GBRP_RAT Q91ZM7_RAT		EC50	5.15		CHEMBL
Thyroid hormone receptor beta	Transcription factor		THB_RAT		IC50	8.74		CHEMBL

External reference:

ID	Source
4022167	VUID
N0000020173	NUI
C0041014	UMLSCUI
D01011	KEGG_DRUG
06LU7C9H1V	UNII
653	INN_ID
61275002	SNOMEDCT_US
350358003	SNOMEDCT_US
4022167	VANDF
d00658	MMSL
004882	NDDF
10814	RXNORM
CHEMBL1544	ChEMBL_ID
DB00279	DRUGBANK_ID
55-06-1	SECONDARY_CAS_RN
T3	PDB_CHEM_ID
CHEBI:18258	CHEBI
CHEMBL1201119	ChEMBL_ID
D014284	MESH_DESCRIPTOR_UI
5920	PUBCHEM_CID
2634	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	16590-303	TABLET	50 1	ORAL	ANDA	13 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	33261-964	TABLET	5 ug	ORAL	ANDA	12 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	39822-0151	INJECTION, SOLUTION	10 ug	INTRAVENOUS	ANDA	12 sections
Triostat	HUMAN PRESCRIPTION DRUG LABEL	1	42023-120	INJECTION	10 ug	INTRAVENOUS	NDA	12 sections
NP Thyroid 15	HUMAN PRESCRIPTION DRUG LABEL	2	42192-327	TABLET	2.25 ug	ORAL	unapproved drug other	21 sections
NP Thyroid 120	HUMAN PRESCRIPTION DRUG LABEL	2	42192-328	TABLET	18 ug	ORAL	unapproved drug other	21 sections
NP Thyroid 30	HUMAN PRESCRIPTION DRUG LABEL	2	42192-329	TABLET	4.50 ug	ORAL	unapproved drug other	21 sections
NP Thyroid 60	HUMAN PRESCRIPTION DRUG LABEL	2	42192-330	TABLET	9 ug	ORAL	unapproved drug other	21 sections
NP Thyroid 90	HUMAN PRESCRIPTION DRUG LABEL	2	42192-331	TABLET	13.50 ug	ORAL	unapproved drug other	21 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42291-417	TABLET	5 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42291-418	TABLET	25 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42291-419	TABLET	50 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42794-018	TABLET	5 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42794-019	TABLET	25 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	42794-020	TABLET	50 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43063-884	TABLET	25 ug	ORAL	ANDA	18 sections
NP Thyroid 60	HUMAN PRESCRIPTION DRUG LABEL	2	45865-566	TABLET	9 ug	ORAL	unapproved drug other	21 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3131	TABLET	5 ug	ORAL	ANDA	19 sections
NP Thyroid 30	HUMAN PRESCRIPTION DRUG LABEL	2	50090-4376	TABLET	4.50 ug	ORAL	unapproved drug other	22 sections
LIOTHYRONINE SODIUM	HUMAN PRESCRIPTION DRUG LABEL	1	51655-122	TABLET	50 ug	ORAL	ANDA	11 sections
NP THYROID 90	HUMAN PRESCRIPTION DRUG LABEL	2	51655-124	TABLET	13.50 ug	ORAL	unapproved drug other	19 sections
NP THYROID 60	HUMAN PRESCRIPTION DRUG LABEL	2	51655-132	TABLET	9 ug	ORAL	unapproved drug other	17 sections
liothyronine sodium	HUMAN PRESCRIPTION DRUG LABEL	1	51655-641	TABLET	25 ug	ORAL	ANDA	10 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	51862-320	TABLET	5 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	51862-321	TABLET	25 ug	ORAL	ANDA	18 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	51862-322	TABLET	50 ug	ORAL	ANDA	18 sections
NP Thyroid 60	HUMAN PRESCRIPTION DRUG LABEL	2	53002-1029	TABLET	9 ug	ORAL	unapproved drug other	22 sections
NP Thyroid 30	HUMAN PRESCRIPTION DRUG LABEL	2	53002-1119	TABLET	4.50 ug	ORAL	unapproved drug other	22 sections
NP Thyroid 90	HUMAN PRESCRIPTION DRUG LABEL	2	53002-5800	TABLET	13.50 ug	ORAL	unapproved drug other	22 sections
Liothyronine Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	53217-361	TABLET	5 ug	ORAL	ANDA	12 sections